or Try an Advanced Search...

    Treatment Of Depression Stocks List

    Symbol Grade Name % Change
    SUPN B Supernus Pharmaceuticals, Inc. -1.69
    BWAY C Brainsway Ltd. -4.30
    STIM D Neuronetics, Inc. -10.13
    View As Page of Charts
    Related Industries: Diagnostics & Research Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Mental Health Neurotechnology Psychiatry Addiction Attention Deficit Hyperactivity Disorder Central Nervous System Disease Chloride Clinical Research Clinical Trial Clinical Trial Product Depression Depressive Disorder Drug Discovery Epilepsy FDA Hyperactivity Disorder Investigational New Drug Major Depressive Disorder Medical Technology Multiple Sclerosis

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Depression stocks.

    Symbol Grade Name Weight
    PJP C PowerShares Dynamic Pharmaceuticals 3.52
    IBRN C iShares Neuroscience and Healthcare ETF 3.22
    XPH C SPDR S&P Pharmaceuticals ETF 2.11
    IZRL B ARK Israel Innovative Technology ETF 2.11
    PILL C Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF 1.46
    View all Treatment Of Depression ETFs...
    Compare ETFs
    Compare IBRN to PILL Compare XPH to IZRL Compare XPH to PILL

        Treatment Of Depression Stocks Recent News

        Date Stock Title
        Nov 13 SUPN Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
        Nov 13 BWAY BrainsWay: Cash Flow Doubts Weigh On The Stock
        Nov 13 STIM Neuronetics Inc (STIM) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Expenses ...
        Nov 13 STIM Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript
        Nov 12 STIM CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
        Nov 12 STIM Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
        Nov 12 BWAY BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript
        Nov 12 SUPN Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
        Nov 12 STIM Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates
        Nov 12 STIM Neuronetics misses top-line and bottom-line estimates; initiates Q4 and updates FY24 outlook
        Nov 12 BWAY BrainsWay GAAP EPS of $0.02 beats by $0.01, revenue of $10.5M beats by $0.41M
        Nov 12 BWAY BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights
        Nov 12 STIM Neuronetics: Q3 Earnings Snapshot
        Nov 12 STIM Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
        Nov 12 STIM Earnings Scheduled For November 12, 2024
        Nov 12 BWAY Earnings Scheduled For November 12, 2024
        Nov 11 BWAY BrainsWay Q3 Earnings Preview
        Related Industries: Diagnostics & Research Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Mental Health Neurotechnology Psychiatry Addiction Attention Deficit Hyperactivity Disorder Central Nervous System Disease Chloride Clinical Research Clinical Trial Clinical Trial Product Depression Depressive Disorder Drug Discovery Epilepsy FDA Hyperactivity Disorder Investigational New Drug Major Depressive Disorder Medical Technology Multiple Sclerosis
        Treatment Of Depression

        Treatment of depression typically involves a combination of medication, psychotherapy, and lifestyle changes. Medication may include antidepressants, which can help to reduce symptoms of depression. Psychotherapy can help to identify and address underlying issues that may be contributing to depression, as well as provide support and guidance. Lifestyle changes may include getting regular exercise, eating a healthy diet, and getting enough sleep. Additionally, engaging in activities that bring joy and pleasure can help to reduce symptoms of depression.

        Browse All Tags